The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.

På svenska

Author

  • O E Olsen
  • K F Wader
  • K Misund
  • T K Våtsveen
  • T B Rø
  • A K Mylin
  • Ingemar Turesson
  • B F Størdal
  • S H Moen
  • T Standal
  • A Waage
  • A Sundan
  • T Holien
Show all

Summary, in English

Multiple myeloma is a malignancy of plasma cells predominantly located in the bone marrow. A number of bone morphogenetic proteins (BMPs) induce apoptosis in myeloma cells in vitro, and with this study we add BMP-9 to the list. BMP-9 has been found in human serum at concentrations that inhibit cancer cell growth in vitro. We here show that the level of BMP-9 in serum was elevated in myeloma patients (median 176 pg/ml, range 8-809) compared with healthy controls (median 110 pg/ml, range 8-359). BMP-9 was also present in the bone marrow and was able to induce apoptosis in 4 out of 11 primary myeloma cell samples by signaling through ALK2. BMP-9-induced apoptosis in myeloma cells was associated with c-MYC downregulation. The effects of BMP-9 were counteracted by membrane-bound (CD105) or soluble endoglin present in the bone marrow microenvironment, suggesting a mechanism for how myeloma cells can evade the tumor suppressing activity of BMP-9 in multiple myeloma.

Publishing year

2014

Language

English

Pages

196-196

Publication/Series

Blood Cancer Journal

Volume

4

Issue

Mar 21

Document type

Journal article

Publisher

Nature Publishing Group

Topic

  • Hematology

Status

Published

ISBN/ISSN/Other

  • ISSN: 2044-5385